Mol2Med™ First-Time-Right Approach for Small Molecule Drug Development

From Lead Optimization to Phase I Manufacturing

Crystal Pharmatech is a global solid state CRO and formulation CDMO specializing in solid form development, preformulation, formulation development, and GMP manufacturing for small molecule drugs.

Our Mol2Med™ First-Time-Right Approach applies a holistic development strategy spanning developability assessment, solid-state research, crystallization development, preformulation studies, and formulation development to guide data-driven decisions and accelerate small molecule programs toward First-in-Human (FIH) studies.

By connecting molecular properties, material attributes, and clinical requirements, Mol2Med™ helps reduce development risk and enable scalable solutions from early discovery through clinical development.

Moving Beyond Fragmented "Fit-for-Purpose" Development Strategies

Many early-stage programs rely on simplified "fit-for-purpose" strategies to move compounds rapidly into early studies. However, decisions made without integrating developability assessment, solid form selection, crystallization development, and formulation strategy often lead to unexpected bioavailability issues, late-stage formulation changes, and costly human PK bridging studies.

The 'Fit-for-Purpose' Trap

Traditional rapid-development strategies — such as powder-in-capsule formulations or simple prototype tablets — may allow compounds to enter early studies quickly. However, these approaches often fail to account for key API physicochemical properties, solid-state behavior, and manufacturability considerations.

As a result, many programs encounter formulation failures in the clinic, requiring significant reformulation efforts and additional PK bridging studies before advancing further in development.

The Mol2Med™ Solution

At Crystal Pharmatech, we address these challenges through our Mol2Med™ First-Time-Right development approach, an integrated strategy designed to guide small molecule drug development from early evaluation through Phase I readiness.

Mol2Med integrates developability assessment, solid-state research, crystallization development, preformulation studies, and formulation design into a unified workflow. By evaluating molecular properties, material behavior, and clinical requirements together, this approach enables informed decision-making that supports successful progression toward First-in-Human (FIH) studies.

Transition to the M3 Philosophy

This integrated development strategy is guided by our M3 Philosophy, which aligns development decisions across three critical dimensions:

Molecule: Clinical requirements, DMPK understanding, pharmacodynamic profile, safety considerations, and molecular characteristics.
Material: API physicochemical, biopharmaceutical, and mechanical properties, stability considerations, and excipient compatibility.
Medicine: Target product profile–driven formulation design, interaction of formulation composition and manufacturing process, impact on critical quality attributes (CQA), and control strategies for drug product performance.

Mol2Med 3-STEP Approach First-Time-Right Direct Route to FIH

First-Time-Right Direct Route to First-In-Human

Our Process

Mol2Med™ First-Time-Right 3-Step Development Approach

The Mol2Med™ framework accelerates small molecule drug development by integrating developability assessment, solid-state research, crystallization development, preformulation studies, and formulation development into a coordinated workflow.

By addressing critical CMC decisions early, this approach helps guide compounds toward First-in-Human (FIH) studies with greater efficiency while reducing downstream development risks.

Step 01

Developability Assessment

Our approach determines the physicochemical properties of lead candidates against industry standards to find the most "developable" lead. For a given preclinical candidate, this determines whether a free form or salt, and a conventional or enabling formulation, should be selected.

Benchmarking against industry standards
High-level strategy for GLP Tox and FIH success

Step 02

Solid Form & Pre-Formulation

This stage begins with comprehensive screening and selection of the optimal crystalline form for the API. Subsequently, we develop an optimal preclinical formulation specifically designed to support robust PK/PD and GLP Tox animal studies.

Optimal Crystalline Form Selection
Support for PK/PD and GLP Tox studies

Step 03

Formulation Dev & CTM Manufacturing

We execute an API-specific strategy that yields the best formulation for Phase I and clinical studies. This allows late-stage development to focus strictly on process optimization without needing significant re-formulation or human PK bridging studies.

First-in-Human (FIH) Formulation
Scalable development through to commercialization

Get Started

Set the Foundation for Clinical Success

The Mol2Med™ First-Time-Right approach establishes a strong foundation for successful clinical development by ensuring that critical CMC decisions are made correctly from the start. By aligning API form selection, formulation design, and manufacturing strategy early in development, this approach enables robust Phase I formulations that are scalable for future clinical studies and commercial manufacturing.

With extensive experience supporting more than 100 drug molecules, Crystal Pharmatech helps sponsors reduce late-stage formulation changes, avoid costly PK bridging studies, and advance small molecule programs toward clinical success with greater confidence and efficiency.

Achieve Your Success with Our Expertise

Have a question or need support with your project? Please complete the form, and our team will get back to you shortly.  

Our capabilities span three specialized platforms:

Small Molecule
Crystal Bio Solutions
Crystal NAX

By providing your e-mail address, you agree to receive an e-mail response from Crystal Pharmatech to your inquiry. The information you submit will be governed by our Privacy Policy.